It's Monday, July 27th. Welcome to Market Foolery. I'm Chris Hill with me today. The

one and only Emily Flipping. Good to see you. Hey, good to see you too, at least

virtually. At least virtually, exactly.

It's a mailbag Monday.

We're going to talk allocation strategy.

We're going to talk retail in a post-Covid world.

We got a couple of headlines to get to.

Let's start with Moderna because shares of Moderna up nearly 10%

after the biotech company said it received an additional

472 million dollars from the government to support the development of a

potential vaccine. This comes on the same day that Moderna is beginning a

phase three study of the vaccine, a much more robust study with 30,000 people.

Yes, this study, which as you mentioned is 30,000 Americans, mostly in areas that have

been highly impacted by the COVID pandemic. Half of those people are getting

placebo, half are getting the vaccine. We'll see how this pans out. Obviously everybody,

including myself, are keeping their fingers crossed that we have

some positive results from this phase three study the first phase three study to be

taking place here in the US but as you mentioned Moderna among a handful of other health care

technology companies are getting payments from the federal government to help speed up

the process of vaccine testing and vaccine development.

I just want to caution investors,

there's probably not going to be a lot of pricing power

...